Clinical Trials · NCT00382239
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- AstraZeneca
- Enrollment
- 153
- Start date
- Sep 2006
- Locations
- 14 sites, Japan
- Primary endpoint
- Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12